ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019
June 18 2019 - 4:01PM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced that Marc Schegerin,
Chief Financial Officer and Head of Strategy, will present at the
BMO Prescriptions for Success Healthcare Conference on June 25,
2019 at 8:00 a.m. ET at the The Mandarin Oriental New York, New
York.
The live webcast of the presentation will be available via the
“Investors & Media” section of ArQule’s website,
www.arqule.com, under “Events & Presentations.” A replay of the
webcast will be available shortly after the conclusion of the
presentation.
About ArQuleArQule is a biopharmaceutical company engaged
in the research and development of targeted therapeutics to treat
cancers and rare diseases. ArQule’s mission is to discover, develop
and commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, in a planned registrational trial with
cohorts in Proteus syndrome and PROS to initiate in 2019, and in
phase 1b in combination with the hormonal therapy, anastrozole, in
patients with advanced endometrial cancer; ARQ 751, a next
generation highly potent and selective AKT inhibitor, in phase 1
for patients with AKT1 and PI3K mutations; and derazantinib, a
multi-kinase inhibitor designed to preferentially inhibit the
fibroblast growth factor receptor (FGFR) family, in a
registrational trial for iCCA in collaboration with Basilea and
Sinovant. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190618005986/en/
Corporate Contact:Kathleen FarrenInvestor Relations
&Executive Assistant to the CFOir@arqule.com
Media Contact:Cait Williamson, Ph.D.LifeSci Public
Relations (646) 751-4366cait@lifescipublicrelations.com
www.ArQule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2024 to May 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From May 2023 to May 2024